Hepatitis
C drugs market was valued USD 18700 million and expected to reach USD 281.55
million by the end of forecasting period reflecting a sluggish CAGR of 1.17% by
2030.
The
hepatitis C drug market is getting bolstered by the increasing disease
prevalence, effective use of government subsidy and reimbursement schemes,
increasing screening opportunities, drug abuse in several countries, unsafe
sex, and others. Market Research Future (MRFR) predicts that this market would
achieve substantial growth in the coming years and cross a high valuation
during the forecast period.
However,
the market has several drawbacks like restraints from regulatory boards, herbal
treatment in developing countries that comes at a negligible cost, the
self-imitating nature of this disease, price war among leading players, and
others are holding back the global market growth. Some companies are also
refraining themselves from moving ahead with the research related to the
disease, which can have a negative impact on the market.
Segmentation:
The
study, containing details of the global hepatitis C drugs market, has been segmented by drug class,
medicine system, route of administration, and end user. This is to simplify the
understanding process and make the outcome more reliable as information in
these segments is backed by data, fetched using scientific methods.
By
drug class, the global discussion on the hepatitis C drugs market has been
segmented into immuno-modulators, anti-viral, and others. The anti-viral
segment is getting a substantial boost due to the growing demand for some of
these drugs to treat coronavirus.
By
medicine system, the study on the global market for hepatitis C drugs includes
alternative, allopathic, and others. The allopathic section has been gaining
much support from the global market.
By
route of administration, the hepatitis C drugs market has been segmented into
injectable, oral, and others. The oral segment has the chance to get improved
valuation due to its convenience.
By
end user, the study on the hepatitis C drug market comprises segments like
hospitals and private. The hospital segment is getting backed by its
superlative infrastructure.
Request Free Sample Copy at:
https://www.marketresearchfuture.com/sample_request/2487
Regional
Analysis:
The
Americas have a better chance of registering high growth due to the presence of
several major market players. In the US, this growth will get backed by a hike
in research projects and the FDA’s recent stance in allowing drugs to percolate
into the market.
Competitive
Landscape:
The
global market for hepatitis C drugs is getting ample traction from several
quarters as various eminent players from the market are effectively boosting
the market prospect. Among these companies, Abbvie Inc, Johnson & Johnson,
Gilead Sciences Inc., GlaxoSmithKline plc, Merck & co. Inc., Bristol-Myers
Squibb, Novartis AG, Hoffmann-la Roche ltd. and others are impacting the global
market with their inspiring business skills and deftly-managed research and
development sector. Apart from these, they are investing a lot in building
partnerships, forming alliances, acquisition, merger, branding, and others to
improve their market position and trigger a holistic growth for the market.
Industry
News:
In
July 2020, Gilead declared that its drug Remdesivir is experiencing an
unprecedented surge due to its effective use in treating people with COVID-19
symptoms. The drug is also known for its efficacy in the treatment of Hepatitis
C. In fact, Gilead has given rights to other generic manufacturers for the
production of this drug to ensure that people all across the world get access
to this. However, this will be for a limited period of time.
In
July 2020, Thermo Fisher Scientific declared the availability of the Thermo
Scientific MAS Omni Infectious Disease quality control sets that would help in
monitoring serological assays for analytes like HIV 1&2, Syphilis,
Hepatitis B & C virus, and HTLV I/II.
Browse
Detailed TOC with COVID-19 Impact Analysis at:
https://www.marketresearchfuture.com/reports/hepatitis-c-drugs-market-2487
About
Market Research Future:
At Market
Research Future (MRFR), we enable our customers to unravel the complexity of
various industries through our Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), & Consulting Services. MRFR team have supreme
objective to provide the optimum quality market research and intelligence
services to our clients.
Contact us:
Market Research
Future (part of Wantstats Research and Media Private Limited),
99 Hudson Street,
5Th Floor,
New York, New
York 10013
United States of
America
+1 628 258 0071
Email: sales@marketresearchfuture.com
Comments
Post a Comment